Generic pain, margin loss: Drug companies may find it hard to adjust with Trump's tariff plans
US President Trump's 25% tariff plan on pharmaceuticals jeopardizes Indian pharma exports, making generics pricier and ...
Amphastar Pharmaceuticals: A Gradual Strategy
Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent ...
US reciprocal tariff on Indian pharma exports to impact American consumers: Pharmexcil
Any potential US tariffs on Indian pharmaceutical exports could primarily affect American consumers, as stated by Pharmexcil. With India sending over USD 8 billion worth of generic drugs annually, ...
Medifast outlines 2025 priorities with plans for $15M-$20M cost savings and new product expansions
Discover how Medifast navigates GLP-1 market shifts with innovative products like OPTAVIA ASCEND, cost-saving initiatives, and growth strategies for 2025.